In the world of medical research, prespecified primary outcomes are supposed to be the immovable target that ensures scientific honesty. Yet, historical monitoring of thousands of clinical trials has long been bogged down by tedious manual curation. Enter the power of artificial intelligence, bringing unprecedented scale to the oversight of clinical evidence. A groundbreaking new … Read more
Every time a new technological marvel enters the medical arena, there are anxieties about obsolescence. Today, as artificial intelligence begins outperforming humans on complex diagnostic tasks and supporting autonomous medical care agents, there is talk of role of medical professionals on clinical care. A recent perspective in the New England Journal of Medicine argues that, … Read more
Bringing a novel medical device from the whiteboard to the operating room is an exhilarating journey, but it frequently hits an abrupt wall at regulatory review. Developers often assume that running a standard battery of laboratory tests will automatically satisfy agency reviewers. In reality, the FDA does not evaluate safety in a vacuum; they evaluate … Read more
Receiving an official Warning Letter from the FDA is a defining moment that can permanently shatter a company’s reputation and bottom line. For Happy Farm Botanicals, Inc., an over-the-counter (OTC) drug manufacturer based in Hyattsville, Maryland, a September 1, 2026, warning letter proved to be the final straw. What began as routine compliance oversight ended … Read more
Navigating the transition from drug approval to market substitution requires a clear understanding of how regulatory bodies evaluate therapeutic equivalence. The FDA’s latest guidance on the topic gives drug sponsors a transparent view into how the agency assigns Orange Book codes. Understanding these principles is vital for biopharma executives, regulatory teams, and commercial strategists looking … Read more
Navigating the clinical trial landscape requires balancing groundbreaking innovation with extreme financial burden, particularly when manufacturing costs threaten to stall development. The FDA offers a formal pathway to recover direct costs for investigational drugs and devices without triggering allegations of premature commercialization, whereby the sponsor can get FDA’s approval to charge for its investigational drugs … Read more
Translating cutting-edge cell and gene therapies (CGTs) from early bench concepts to commercial realities presents a complex regulatory landscape. FDA’s latest FAQ guidance adds to its previous suggestions regarding regulatory interactions, chemistry, manufacturing, and controls (CMC), nonclinical evaluation, and clinical design. For sponsors navigating regulatory hurdles, this guidance provides an operational blueprint to clarify agency … Read more
Developing active immunotherapy products (ACTIMPs) has long presented a unique bioanalytical bottleneck because therapeutic efficacy relies on complex host immune responses rather than straightforward direct activity. For years, drug developers have wrestled with static legacy testing expectations that fail to accommodate multi-antigen vectors, cellular matrices, or patient-specific neoantigen vaccines. The FDA’s new guidance outlines a … Read more
Choosing between an ANDA (generic) and a 505(b)(2) application determines your development cost, timeline, and clinical burden. The FDA’s updated guidance, released this week, clarifies how regulators evaluate the applicability of either of these pathways to new applications. The two pathways are vastly different in their development programs and expected returns presenting a core financial … Read more
Traditional software validation frameworks are proving ill-equipped for the fluid, unpredictable nature of generative artificial intelligence in healthcare. As medical device developers navigate open-ended prompts, hallucination risks, and third-party foundation models, the FDA’s Center for Devices and Radiological Health (CDRH) has released a landmark discussion paper outlining a dedicated regulatory approach for GenAI-enabled devices. While … Read more
